These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 28866669

  • 1. Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload.
    Du Y, Long Z, Chen M, Han B, Hou B, Feng F.
    Acta Haematol; 2017; 138(2):119-128. PubMed ID: 28866669
    [Abstract] [Full Text] [Related]

  • 2. Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.
    Cheong JW, Kim HJ, Lee KH, Yoon SS, Lee JH, Park HS, Kim HY, Shim H, Seong CM, Kim CS, Chung J, Hyun MS, Jo DY, Jung CW, Sohn SK, Yoon HJ, Kim BS, Joo YD, Park CY, Min YH, Korean Society of Hematology Acute Myeloid Leukemia/Myelodysplastic Syndrome Working Party.
    Transfusion; 2014 Jun; 54(6):1542-51. PubMed ID: 24313463
    [Abstract] [Full Text] [Related]

  • 3. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions.
    Chacko J, Pennell DJ, Tanner MA, Hamblin TJ, Wonke B, Levy T, Thomas PW, Killick SB.
    Br J Haematol; 2007 Sep; 138(5):587-93. PubMed ID: 17610536
    [Abstract] [Full Text] [Related]

  • 4. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
    Kim IH, Moon JH, Lim SN, Sohn SK, Kim HG, Lee GW, Kim YS, Lee HS, Kwon KY, Kim SH, Park KT, Chung JS, Lee WS, Lee SM, Hyun MS, Kim H, Ryoo HM, Bae SH, Joo YD.
    Transfusion; 2015 Jul; 55(7):1613-20. PubMed ID: 25764017
    [Abstract] [Full Text] [Related]

  • 6. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality.
    Takatoku M, Uchiyama T, Okamoto S, Kanakura Y, Sawada K, Tomonaga M, Nakao S, Nakahata T, Harada M, Murate T, Ozawa K, Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes.
    Eur J Haematol; 2007 Jun; 78(6):487-94. PubMed ID: 17391310
    [Abstract] [Full Text] [Related]

  • 7. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S.
    Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
    [Abstract] [Full Text] [Related]

  • 8. [Study of iron overload assessment by T2* magnetic resonance imaging in patients with myelodysplastic syndromes].
    Song LL, Lu HY, Xiao C, Wu LY, Wu D, Su JY, Zhou LY, Chang CK.
    Zhonghua Xue Ye Xue Za Zhi; 2019 Mar 14; 40(3):222-226. PubMed ID: 30929390
    [Abstract] [Full Text] [Related]

  • 9. Hepatic and cardiac and iron overload detected by T2* magnetic resonance (MRI) in patients with myelodisplastic syndrome: A cross-sectional study.
    Mantovani LF, Santos FPS, Perini GF, Nascimento CMB, Silva LP, Wroclawski CK, Esposito BP, Ribeiro MSS, Velloso EDRP, Nomura CH, Kay FU, Baroni RH, Hamerschlak N, Schuster S.
    Leuk Res; 2019 Jan 14; 76():53-57. PubMed ID: 30572266
    [Abstract] [Full Text] [Related]

  • 10. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.
    Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Domokos G, Roubert B, Rose C, EPIC study investigators.
    Leuk Res; 2010 Sep 14; 34(9):1143-50. PubMed ID: 20451251
    [Abstract] [Full Text] [Related]

  • 11. [MRI monitoring in diagnosis and follow-up of iron overload].
    Zhang Q, Hou B, Wang L, Du Y, Han B, Feng F.
    Zhonghua Xue Ye Xue Za Zhi; 2015 Apr 14; 36(4):302-6. PubMed ID: 25916291
    [Abstract] [Full Text] [Related]

  • 12. [Study on HFE gene mutations in patients with myelodysplastic syndromes and aplastic anemia].
    Nie L, Ai XF, Zheng YZ, Li QH, Yang L, Xiao ZJ.
    Zhonghua Xue Ye Xue Za Zhi; 2009 Apr 14; 30(4):223-8. PubMed ID: 19731820
    [Abstract] [Full Text] [Related]

  • 13. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2009 Apr 14; 33(5):312-22. PubMed ID: 19814677
    [Abstract] [Full Text] [Related]

  • 14. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
    Dreyfus F.
    Blood Rev; 2008 Dec 14; 22 Suppl 2():S29-34. PubMed ID: 19059054
    [Abstract] [Full Text] [Related]

  • 15. [The role of iron metabolism in myelodysplastic syndromes].
    Finelli C, Clissa C, Stanzani M.
    Recenti Prog Med; 2014 Mar 14; 105(3):123-6. PubMed ID: 24675455
    [Abstract] [Full Text] [Related]

  • 16. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique.
    Konen E, Ghoti H, Goitein O, Winder A, Kushnir T, Eshet Y, Rachmilewitz E.
    Am J Hematol; 2007 Nov 14; 82(11):1013-6. PubMed ID: 17654681
    [Abstract] [Full Text] [Related]

  • 17. Longitudinal MRI and Ferritin Monitoring of Iron Overload in Chronically Transfused and Chelated Children With Sickle Cell Anemia and Thalassemia Major.
    Aubart M, Ou P, Elie C, Canniffe C, Kutty S, Delos V, Graffigne C, de Montalembert M, Brousse V.
    J Pediatr Hematol Oncol; 2016 Oct 14; 38(7):497-502. PubMed ID: 27548334
    [Abstract] [Full Text] [Related]

  • 18. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
    Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P, Fenaux P, GFM (Groupe Francophone des Myélodysplasies).
    Leuk Res; 2010 Jul 14; 34(7):864-70. PubMed ID: 20129667
    [Abstract] [Full Text] [Related]

  • 19. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
    Remacha AF, Arrizabalaga B, Del Cañizo C, Sanz G, Villegas A.
    Ann Hematol; 2010 Feb 14; 89(2):147-54. PubMed ID: 19690857
    [Abstract] [Full Text] [Related]

  • 20. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
    Ha SY, Mok AS, Chu WC, Raskalkar DD, Cheuk DK, Chiang AK, Ho MH, Chan GC.
    Hemoglobin; 2009 Feb 14; 33(5):323-31. PubMed ID: 19814678
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.